The need for a new vaccine against lyme borreliosis

Expert Review of Vaccines

Volumn 12, Issue 2, 2013, Pages 101-103

  Barrett, P Noel ^a   Portsmouth, Daniel ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

Borrelia; borreliosis; lyme; Osp; OspA; tick; vaccine

Indexed keywords

EPITOPE; LYME DISEASE VACCINE;

ANTIBODY RESPONSE; ARTHRITIS; CROSS REACTION; DRUG WITHDRAWAL; EDITORIAL; HELPER CELL; HUMAN; IMMUNITY; IMMUNOGENICITY; LYME DISEASE; PRIORITY JOURNAL; SEROTYPE; VACCINATION;

ANTIGENS, SURFACE; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LIPOPROTEINS; LYME DISEASE; UNITED STATES;

EID: 84874104220     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.141     Document Type: Editorial

References (18)

1. Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet 379(9814), 461-473 (2012).
2. Steere AC, Livey I. Lyme disease vaccines. In: Vaccines. Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders, PA, USA (2012).
3. Plotkin SA. Correcting a public health fiasco: the need for a new vaccine against Lyme disease. Clin. Infect. Dis. 52(Suppl. 3), s271-s275 (2011).
4. Stanek G, Fingerle V, Hunfeld KP et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin. Microbiol. Infect. 17(1), 69-79 (2011).
5. Nadelman RB, Wormser GP. Reinfection in patients with Lyme disease. Clin. Infect. Dis. 45(8), 1032-1038 (2007).
6. CDC. Notices to Readers: Final 2011 Reports of Nationally Notifiable Infectious Diseases 61(32), 624-637 (2012).
7. Lindgren E, Jaenson TGT. Lyme Borreliosis in Europe: Influences of Climate and Climate Change, Epidemiology, Ecology and Adaptation Measures. WHO, Geneva, Switzerland (2006).
8. Rizzoli A, Hauffe H, Carpi G, Vourc H G, Neteler M, Rosa R. Lyme borreliosis in Europe. Euro Surveill. 16(27), pii:19906 (2011).
9. Shen AK, Mead PS, Beard CB. The Lyme disease vaccine-a public health perspective. Clin. Infect. Dis. 52(Suppl. 3), s247-s252 (2011).
10. Sigal LH, Zahradnik JM, Lavin P et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N. Engl. J. Med. 339(4), 216-222 (1998).
11. Steere AC, Sikand VK, Meurice F et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outersurface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N. Engl. J. Med. 339(4), 209-215 (1998).
12. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Recommendations for the use of Lyme disease vaccine. MMWR Recomm. Rep. 48RR-7, 1-5 (1999).
13. Poland GA. Vaccines against Lyme disease: What happened and what lessons can we learn? Clin. Infect. Dis. 52(Suppl. 3), s253-s258 (2011).
14. Gross DM, Forsthuber T, Tary-Lehmann M et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281(5377), 703-706 (1998).
15. Lathrop SL, Ball R, Haber P et al. Adverse event reports following vaccination for Lyme disease: December 1998-July 2000. Vaccine 20(11-12), 1603-1608 (2002).
16. Livey I, O'Rourke M, Traweger A et al. A new approach to a Lyme disease vaccine. Clin. Infect. Dis. 52(Suppl. 3), s266-s270 (2011).
17. Koide S, Yang X, Huang X, Dunn JJ, Luft BJ. Structure-based design of a secondgeneration Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. J. Mol. Biol. 350(2), 290-299 (2005).
18. Luft BJ, Dunn JJ, Lawson CL. Approaches toward the directed design of a vaccine against Borrelia burgdorferi. J. Infect. Dis. 185(Suppl. 1), S46-S51 (2002).